<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl3" position="float">
 <label>Table 3</label>
 <caption>
  <p>Regional and global estimates of coverage of needle and syringe programmes, opioid substitution therapy, and HIV testing for PWID</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th align="left">
     <bold>Estimated number of PWID (UI)</bold>
    </th>
    <th colspan="3" align="left">
     <bold>Needle and syringe programmes</bold>
     <hr/>
    </th>
    <th colspan="4" align="left">
     <bold>Opioid substitution therapy</bold>
     <hr/>
    </th>
    <th colspan="2" align="left">
     <bold>HIV testing</bold>
     <hr/>
    </th>
   </tr>
   <tr>
    <th/>
    <th/>
    <th align="left">Countries implementing (% ERPP)</th>
    <th align="left">Countries with data (% ERPP)</th>
    <th align="left">Needle-syringes per PWID per year (UI)</th>
    <th align="left">Countries implementing (% ERPP)</th>
    <th align="left">Countries with data (% ERPP)</th>
    <th align="left">Clients per 100 PWID (UI)</th>
    <th align="left">Clients per 100 primary opioid injectors (UI)</th>
    <th align="left">Countries with data (% ERPP)</th>
    <th align="left">Number of PWID receiving HIV tests per 100 PWID (UI)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Eastern Europe</td>
    <td align="left">3 020 000 (1 653 500–5 008 000)</td>
    <td align="left">17 (100%)</td>
    <td align="left">17 (100%)</td>
    <td align="left">15 (9–27)</td>
    <td align="left">16 (41%)</td>
    <td align="left">17 (100%)</td>
    <td align="left">1 (&lt;1–2)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">13 (98%)</td>
    <td align="left">15 (9–27)</td>
   </tr>
   <tr>
    <td align="left">Western Europe</td>
    <td align="left">1 009 500 (686 500–1 386 500)</td>
    <td align="left">29 (100%)</td>
    <td align="left">22 (26%)</td>
    <td align="left">166 (118–243)</td>
    <td align="left">30 (100%)</td>
    <td align="left">29 (100%)</td>
    <td align="left">64 (46–95)</td>
    <td align="left">94 (67–GTP)</td>
    <td align="left">7 (7%)</td>
    <td align="left">15 (11–22)</td>
   </tr>
   <tr>
    <td align="left">East and southeast Asia</td>
    <td align="left">3 989 000 (3 041 000–4 955 000)</td>
    <td align="left">10 (88%)</td>
    <td align="left">12 (92%)</td>
    <td align="left">16 (13–21)</td>
    <td align="left">9 (87%)</td>
    <td align="left">16 (100%)</td>
    <td align="left">8 (7–11)</td>
    <td align="left">9 (7–11)</td>
    <td align="left">3 (10%)</td>
    <td align="left">40 (33–53)</td>
   </tr>
   <tr>
    <td align="left">South Asia</td>
    <td align="left">1 023 500 (783 500–1 263 000)</td>
    <td align="left">6 (100%)</td>
    <td align="left">7 (85%)</td>
    <td align="left">43 (35–56)</td>
    <td align="left">6 (56%)</td>
    <td align="left">8 (93%)</td>
    <td align="left">82 (67–GTP)</td>
    <td align="left">91 (73–GTP)</td>
    <td align="left">4 (18%)</td>
    <td align="left">7 (6–10)</td>
   </tr>
   <tr>
    <td align="left">Central Asia</td>
    <td align="left">281 500 (189 500–416 500)</td>
    <td align="left">4 (92%)</td>
    <td align="left">5 (100%)</td>
    <td align="left">115 (78–172)</td>
    <td align="left">3 (58%)</td>
    <td align="left">5 (100%)</td>
    <td align="left">1 (&lt;1–1)</td>
    <td align="left">1 (1–2)</td>
    <td align="left">3 (58%)</td>
    <td align="left">41 (28–61)</td>
   </tr>
   <tr>
    <td align="left">Caribbean</td>
    <td align="left">79 500 (53 000–118 000)</td>
    <td align="left">2 (63%)</td>
    <td align="left">6 (100%)</td>
    <td align="left">6 (4–8)</td>
    <td align="left">1 (35%)</td>
    <td align="left">5 (65%)</td>
    <td align="left">8 (6–13)</td>
    <td align="left">11 (7–18)</td>
    <td align="left">0 (0%)</td>
    <td align="left">NK</td>
   </tr>
   <tr>
    <td align="left">Latin America</td>
    <td align="left">1 823 000 (1 392 000–2 380 000)</td>
    <td align="left">6 (75%)</td>
    <td align="left">13 (33%)</td>
    <td align="left">6 (5–8)</td>
    <td align="left">3 (21%)</td>
    <td align="left">17 (87%)</td>
    <td align="left">3 (2–4)</td>
    <td align="left">3 (3–5)</td>
    <td align="left">1 (8%)</td>
    <td align="left">2 (1–2)</td>
   </tr>
   <tr>
    <td align="left">North America</td>
    <td align="left">2 557 000 (1 498 500–4 428 000)</td>
    <td align="left">2 (100%)</td>
    <td align="left">2 (100%)</td>
    <td align="left">39 (22–66)</td>
    <td align="left">2 (100%)</td>
    <td align="left">2 (100%)</td>
    <td align="left">20 (11–34)</td>
    <td align="left">27 (16–61)</td>
    <td align="left">0 (0%)</td>
    <td align="left">NK</td>
   </tr>
   <tr>
    <td align="left">Australasia</td>
    <td align="left">115 500 (83 000–148 000)</td>
    <td align="left">2 (100%)</td>
    <td align="left">2 (100%)</td>
    <td align="left">396 (309–550)</td>
    <td align="left">2 (100%)</td>
    <td align="left">2 (100%)</td>
    <td align="left">46 (36–64)</td>
    <td align="left">73 (56–GTP)</td>
    <td align="left">0 (0%)</td>
    <td align="left">NK</td>
   </tr>
   <tr>
    <td align="left">Pacific Islands</td>
    <td align="left">22 500 (15 000–33 500)</td>
    <td align="left">0 (0%)</td>
    <td align="left">15 (100%)</td>
    <td align="left">0 (0–0)</td>
    <td align="left">0 (0%)</td>
    <td align="left">15 (100%)</td>
    <td align="left">0 (0–0)</td>
    <td align="left">0 (0–0)</td>
    <td align="left">0 (0%)</td>
    <td align="left">NK</td>
   </tr>
   <tr>
    <td align="left">Middle East and north Africa</td>
    <td align="left">349 500 (177 500–521 500)</td>
    <td align="left">8 (36%)</td>
    <td align="left">21 (100%)</td>
    <td align="left">2 (1–4)</td>
    <td align="left">7 (33%)</td>
    <td align="left">19 (98%)</td>
    <td align="left">6 (4–12)</td>
    <td align="left">6 (4–11)</td>
    <td align="left">6 (41%)</td>
    <td align="left">2 (2–4)</td>
   </tr>
   <tr>
    <td align="left">Sub-Saharan Africa</td>
    <td align="left">1 378 000 (645 500–3 080 000)</td>
    <td align="left">7 (38%)</td>
    <td align="left">36 (100%)</td>
    <td align="left">2 (&lt;1–4)</td>
    <td align="left">8 (37%)</td>
    <td align="left">31 (91%)</td>
    <td align="left">1 (&lt;1–2)</td>
    <td align="left">1 (&lt;1–4)</td>
    <td align="left">3 (31%)</td>
    <td align="left">1 (&lt;1–3)</td>
   </tr>
   <tr>
    <td align="left">Global</td>
    <td align="left">15 648 000 (10 219 000–23 737 500)</td>
    <td align="left">93 (86%)</td>
    <td align="left">158 (82%)</td>
    <td align="left">33 (21–50)</td>
    <td align="left">87 (64%)</td>
    <td align="left">166 (97%)</td>
    <td align="left">16 (11–25)</td>
    <td align="left">19 (13–31)</td>
    <td align="left">..</td>
    <td align="left">..</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Estimated number of people who inject drugs from Degenhardt and colleagues.
    <xref rid="bib1" ref-type="bibr">
     <sup>1</sup>
    </xref> Number of countries with data includes countries where injecting is confirmed to occur but intervention is known to not be implemented (ie, coverage estimate is zero); therefore number of countries with data for an intervention can exceed number of countries implementing an intervention. UI=uncertainty interval. PWID=people who inject drugs. NSP=needle and syringe programmes. OST=opioid substitution therapy. ERPP=estimated regional PWID population. GTP=estimate greater than parity. NK=not known.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
